Feature | September 19, 2014

Large Study Offers Real World Comparison of Blood Thinner Use In Heart Attack Patients

Study Blood Thinner Heart Attack Patients

September 19, 2014 — The largest prospective longitudinal study of acute myocardial infarction (MI) patients offers unique insight into the use, safety and effectiveness of blood thinners prasugrel and clopidogrel in hospitals across the United States. Findings were reported Sept. 15 at the 2014 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Although randomized clinical trials have established the efficacy of prasugrel in acute MI patients, limited data is available on the comparative effectiveness and safety of prasugrel vs. clopidogrel therapy when used in routine clinical practice in the United States.

The TRANSLATE-ACS trial is a multicenter, prospective, observational study that compared prasugrel and clopidogrel among myocardial infarction (MI) patients undergoing percutaneous coronary intervention (PCI). Primary endpoints were a composite of major adverse coronary events (MACE: all-cause death, MI, stroke or unplanned coronary revascularization), stent thrombosis, as well as GUSTO moderate to severe bleeding at one year follow-up.

The trial observed physician-directed patterns of prasugrel vs. clopidogrel use among 11,969 patients treated with PCI at 233 hospitals in the United States. Prasugrel was used in 3,123 MI patients (25.5 percent) at the time of PCI. Patients treated with prasugrel were younger (median 57 vs. 61 years, p<0.0001), more likely to present with ST elevated myocardial infarction (STEMI, the most serious form of a heart attack), and less likely to have prior MI (14.6 percent vs. 21.3 percent, <0.0001) or diabetes (24.6 percent vs. 27.2 percent, p= 0.003) than clopidogrel-treated patients.

While unadjusted comparisons demonstrated lower MACE in patients receiving prasugrel vs. clopidogrel, these differences were no longer significant after risk adjustment (Adj. HR=1.03, 95% CI, 0.92 – 1.16, p=0.59). However prasugrel was associated with significantly lower adjusted risk of definite stent thrombosis per ARC criteria. (0.97 percent vs. 1.24 percent, p=0.11; Adj. HR 0.54 (0.33-0.89), p=0.02). Among all-comers, prasugrel was also associated with significantly higher adjusted bleeding risk relative to clopidogrel (Adj. HR=1.30, 95% CI, 1.04-1.63, p=0.02).  In propensity matched secondary analyses, the associations with MACE and stent thrombosis showed consistent results, whereas the association with bleeding was no longer statistically significant.

“TRANSLATE-ACS represents the largest prospective longitudinal study of acute MI patients undergoing PCI in contemporary community practice in the United States.” said lead investigator Tracy Y. Wang, M.D., MHS, MS. Wang is an associate professor of Medicine at Duke University. “This observational study found that patients treated with prasugrel vs. clopidogrel significantly differ, and the trial provided a unique opportunity to compare their effectiveness and safety in the real world.”

The TRANSLATE-ACS trial was funded by Lilly USA and Daiichi Sankyo. Wang reported research grant support to the Duke Clinical Research Institute from Daiichi Sankyo, Eli Lilly, Astra Zeneca, Gilead Sciences and Glaxo Smith Kline.

For more information: www.crf.org, www.tctconference.com

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init